(Reuters) – The U.S. Supreme Court on Thursday turned down Novartis Pharmaceuticals Corp’s bid to block the launch of generic versions of the company’s blockbuster multiple sclerosis drug Gilenya in a dispute with China’s HEC Pharm Co Ltd and other generic drugmakers.
Novartis had asked the justices to stay a lower court’s ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company’s third highest-selling drug last year with $2.8 billion in sales.
(Reporting by Nate Raymond in Boston; Editing by Chris Reese)
